Henry Schein (HSIC) : Ashfield Capital Partners reduced its stake in Henry Schein by 6.22% during the most recent quarter end. The investment management company now holds a total of 138,101 shares of Henry Schein which is valued at $23.7 Million after selling 9,167 shares in Henry Schein , the firm said in a disclosure report filed with the SEC on May 13, 2016.Henry Schein makes up approximately 1.75% of Ashfield Capital Partners’s portfolio.
Other Hedge Funds, Including , Caisse De Depot Et Placement Du Quebec reduced its stake in HSIC by selling 1,193 shares or 3.38% in the most recent quarter. The Hedge Fund company now holds 34,107 shares of HSIC which is valued at $5.9 Million. Henry Schein makes up approx 0.02% of Caisse De Depot Et Placement Du Quebec’s portfolio.Canada Pension Plan Investment Board boosted its stake in HSIC in the latest quarter, The investment management firm added 17,791 additional shares and now holds a total of 26,101 shares of Henry Schein which is valued at $4.5 Million. Henry Schein makes up approx 0.02% of Canada Pension Plan Investment Board’s portfolio.Victory Capital Management Inc reduced its stake in HSIC by selling 3,856 shares or 47.46% in the most recent quarter. The Hedge Fund company now holds 4,268 shares of HSIC which is valued at $733,968.Keybank National Associationoh boosted its stake in HSIC in the latest quarter, The investment management firm added 4,509 additional shares and now holds a total of 259,731 shares of Henry Schein which is valued at $44.7 Million. Henry Schein makes up approx 0.30% of Keybank National Associationoh’s portfolio.Lmr Partners Llp reduced its stake in HSIC by selling 282 shares or 10.43% in the most recent quarter. The Hedge Fund company now holds 2,423 shares of HSIC which is valued at $411,910. Henry Schein makes up approx 0.06% of Lmr Partners Llp’s portfolio.
Henry Schein closed down -1.21 points or -0.70% at $171.53 with 3,79,302 shares getting traded on Wednesday. Post opening the session at $172.86, the shares hit an intraday low of $171.24 and an intraday high of $173.32 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.